Longboard Pharmaceuticals (NASDAQ:LBPH) has announced interim data from its PACIFIC Open-Label Extension (OLE) Study evaluating bexicaserin (LP352) for participants with developmental and epileptic encephalopathies (DEEs).

The study showed a 56.1% median decrease in seizure frequency over six months, with participants previously on placebo achieving a 57.3% reduction upon transitioning to bexicaserin.

Dr. Randall Kaye, Chief Medical Officer at Longboard Pharmaceuticals, expressed his enthusiasm about the results, stating, “We are thrilled to see a sustained, durable response in seizure reduction and a favorable safety and tolerability profile.” 

The PACIFIC OLE Study involved 41 participants with DEEs, all of whom continued from the earlier PACIFIC Study, with 95.1% remaining in the ongoing extension.

With the successful interim results, Longboard Pharmaceuticals is actively preparing for a global Phase 3 program, with an End of Phase 2 meeting scheduled for this summer.